Search company, investor...

Bullfrog AI

bullfrogai.com

Founded Year

2017

Stage

Debt | Alive

Total Raised

$200K

About Bullfrog AI

Bullfrog AI is a digital biopharma company that uses its bfLEAP platform to help biopharmaceutical companies find success in their clinical development programs. It was founded in 2017 and is based in Gaithersburg, Maryland.

Headquarters Location

325 Ellington Blvd

Gaithersburg, Maryland, 20878,

United States

Missing: Bullfrog AI's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bullfrog AI's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Bullfrog AI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Bullfrog AI in 1 CB Insights research brief, most recently on May 7, 2020.

Expert Collections containing Bullfrog AI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bullfrog AI is included in 3 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Bullfrog AI News

13:00 ET Global AI-based Clinical Trials Solution Provider Market to Reach $7.8 Billion by 2030 at a CAGR of 22%

Nov 17, 2022

News provided by Share this article Share this article The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030 and is expected to expand at a CAGR of 22.0% over the forecast period. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse application provided by AI in the field of drug studies is impelling the growth. Based on the phase of the clinical trial, Phase II dominated the market with a share of 47.2% in 2021 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase. In 2021, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth. In 2021, based on end-use, pharmaceutical companies accounted for the highest revenue share in the market. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and overall drug discovery process, thereby, impelling the growth. North America dominated the market and accounted for revenue share of 43.8% in 2021. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region. The AI-based technologies witnessed a surge in their adoption due to the outburst of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth. Key Topics Covered: Chapter 2 Executive Summary Chapter 4 AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis Chapter 5 AI-based Clinical Trial Solution Providers Market: Therapeutic Application Estimates & Trend Analysis Chapter 6 AI-based Clinical Trial Solution Providers Market: End-Use Estimates & Trend Analysis Chapter 7 AI-based Clinical Trial Solution Providers Market: Regional Estimates & Trend Analysis, By Clinical Trial Phase, Therapeutic Application & End-Use Chapter 8 Company Profiles

Bullfrog AI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bullfrog AI Rank

Bullfrog AI Frequently Asked Questions (FAQ)

  • When was Bullfrog AI founded?

    Bullfrog AI was founded in 2017.

  • Where is Bullfrog AI's headquarters?

    Bullfrog AI's headquarters is located at 325 Ellington Blvd, Gaithersburg.

  • What is Bullfrog AI's latest funding round?

    Bullfrog AI's latest funding round is Debt.

  • How much did Bullfrog AI raise?

    Bullfrog AI raised a total of $200K.

  • Who are the investors of Bullfrog AI?

    Investors of Bullfrog AI include Maryland Technology Development Corporation and Johns Hopkins University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.